Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Merck
Mallinckrodt
Boehringer Ingelheim

Last Updated: May 25, 2022

Investigational Drug Information for BKM120


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug BKM120?

BKM120 is an investigational drug.

There have been 82 clinical trials for BKM120. The most recent clinical trial was a Phase 3 trial, which was initiated on October 3rd 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are four hundred and forty-eight US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for BKM120
TitleSponsorPhase
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid TumorsAdlai Nortye Biopharma Co., Ltd.Phase 1
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaNovartisPhase 1
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaEmory UniversityPhase 1

See all BKM120 clinical trials

Clinical Trial Summary for BKM120

Top disease conditions for BKM120
Top clinical trial sponsors for BKM120

See all BKM120 clinical trials

US Patents for BKM120

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BKM120 See Plans and Pricing Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
BKM120 See Plans and Pricing Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) See Plans and Pricing
BKM120 See Plans and Pricing Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
BKM120 See Plans and Pricing Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BKM120

Drugname Country Document Number Estimated Expiration Related US Patent
BKM120 Australia AU2015231053 2034-03-21 See Plans and Pricing
BKM120 Brazil BR112016021620 2034-03-21 See Plans and Pricing
BKM120 Canada CA2943339 2034-03-21 See Plans and Pricing
BKM120 China CN106231900 2034-03-21 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Merck
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.